Repligen (NASDAQ:RGEN) Now Covered by TD Cowen

Research analysts at TD Cowen started coverage on shares of Repligen (NASDAQ:RGEN) in a research report issued on Monday, Marketbeat.com reports. The firm set a “buy” rating and a $200.00 price target on the biotechnology company’s stock. TD Cowen’s price target would suggest a potential upside of 33.79% from the company’s current price.

Other equities research analysts also recently issued research reports about the company. Wolfe Research assumed coverage on Repligen in a research report on Thursday, November 14th. They set a “peer perform” rating for the company. Canaccord Genuity Group assumed coverage on shares of Repligen in a research note on Tuesday, December 17th. They issued a “hold” rating and a $165.00 target price for the company. Canaccord Genuity Group initiated coverage on Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price target for the company. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a report on Friday, January 3rd. Finally, HC Wainwright reduced their target price on Repligen from $240.00 to $180.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Six research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and a consensus target price of $186.00.

Repligen Stock Performance

NASDAQ:RGEN opened at $149.49 on Monday. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen has a twelve month low of $113.50 and a twelve month high of $211.13. The company has a market capitalization of $8.38 billion, a P/E ratio of -404.02, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. The firm has a 50-day moving average price of $155.43 and a two-hundred day moving average price of $149.08.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.34 by $0.09. The firm had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. Repligen’s revenue for the quarter was up 9.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.23 EPS. As a group, research analysts expect that Repligen will post 1.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Repligen

Hedge funds and other institutional investors have recently modified their holdings of the stock. Signaturefd LLC increased its position in shares of Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 124 shares during the period. UMB Bank n.a. increased its position in shares of Repligen by 138.3% during the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares in the last quarter. Blue Trust Inc. raised its stake in shares of Repligen by 113.4% in the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 127 shares during the last quarter. Resources Management Corp CT ADV bought a new position in Repligen in the 3rd quarter valued at $37,000. Finally, Quarry LP raised its holdings in shares of Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 239 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.